- 专利标题： ADOPTIVE T CELL THERAPY 2
-
申请号： US16625443申请日： 2018-06-22
-
公开(公告)号： US20220226373A1公开(公告)日： 2022-07-21
- 发明人: Emily BLYTH , Leighton CLANCY , David GOTTLIEB , Kenneth MICKLETHWAITE
- 申请人： THE WESTMEAD INSTITUTE FOR MEDICAL RESEARCH , THE UNIVERSITY OF SYDNEY , WESTERN SYDNEY LOCAL HEALTH DISTRICT , NEW SOUTH WALES HEALTH PATHOLOGY
- 申请人地址： AU New South Wales; AU New South Wales; AU New South Wales; AU New South Wales
- 专利权人： THE WESTMEAD INSTITUTE FOR MEDICAL RESEARCH,THE UNIVERSITY OF SYDNEY,WESTERN SYDNEY LOCAL HEALTH DISTRICT,NEW SOUTH WALES HEALTH PATHOLOGY
- 当前专利权人： THE WESTMEAD INSTITUTE FOR MEDICAL RESEARCH,THE UNIVERSITY OF SYDNEY,WESTERN SYDNEY LOCAL HEALTH DISTRICT,NEW SOUTH WALES HEALTH PATHOLOGY
- 当前专利权人地址： AU New South Wales; AU New South Wales; AU New South Wales; AU New South Wales
- 优先权： AU2017902407 20170622
- 国际申请： PCT/AU2018/050630 WO 20180622
- 主分类号： A61K35/17
- IPC分类号： A61K35/17 ; A61K39/00 ; A61K39/12 ; A61P31/10 ; A61P31/12 ; A61P35/00
摘要：
The present disclosure relates to compositions comprising isolated T cells, with activity against a fungal antigen, a viral antigen or a tumour antigen, wherein the composition comprises a defined number or defined ratio of T cells. Described herein are compositions comprising at least two populations of T cells, the compositions being suitable for treating various diseases and disorders.
公开/授权文献
- US11951127B2 Adoptive T cell therapy 2 公开/授权日：2024-04-09
信息查询
IPC分类:
